Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of “Hold” by Brokerages

Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM) have been assigned an average rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $20.00.

Several research analysts recently weighed in on CTNM shares. Wall Street Zen raised Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley boosted their price target on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Friday, July 17th.

Contineum Therapeutics Price Performance

CTNM opened at $14.06 on Friday. The business has a 50 day moving average price of $13.51 and a two-hundred day moving average price of $13.44. The company has a market capitalization of $525.70 million, a price-to-earnings ratio of -7.21 and a beta of 0.70. Contineum Therapeutics has a 1-year low of $5.07 and a 1-year high of $16.91.

Contineum Therapeutics (NASDAQ:CTNM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.16. Equities analysts expect that Contineum Therapeutics will post -1.68 EPS for the current fiscal year.

Institutional Trading of Contineum Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CTNM. Strs Ohio acquired a new stake in Contineum Therapeutics during the first quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. acquired a new position in Contineum Therapeutics in the fourth quarter worth approximately $43,000. Qube Research & Technologies Ltd bought a new position in shares of Contineum Therapeutics in the second quarter valued at $43,000. Marex Group plc bought a new position in shares of Contineum Therapeutics in the second quarter valued at $45,000. Finally, Royal Bank of Canada lifted its position in shares of Contineum Therapeutics by 73.5% during the 1st quarter. Royal Bank of Canada now owns 5,794 shares of the company’s stock valued at $76,000 after acquiring an additional 2,454 shares during the last quarter.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.